Anemoside B4 inhibits SARS-CoV-2 replication in vitro and in vivo.

AB4, a saponin from [plant], shows potential antiviral activity against SARS-CoV-2. Study aims to determine mechanism. Important for developing new treatments against COVID-19.

Xiao M et al (2023).

Chin Herb Med.

DOI:

10.1016/j.chmed.2023.09.005

PubMed:

38375049

Multi-target drugs for the treatment of cognitive impairment and fatigue in post-COVID syndrome: focus on Ginkgo biloba and Rhodiola rosea.

Post-COVID syndrome leads to cognitive impairment, depression, and fatigue due to neuroinflammation, oxidative stress, and mitochondrial dysfunction. Herbal drugs like Ginkgo biloba and Rhodiola rosea may improve cognition, reduce fatigue and depression, but more research is required.

Mueller JK and Müller WE (2024).

J Neural Transm (Vienna).

DOI:

10.1007/s00702-024-02749-3

PubMed:

38347175

Evaluation of the inhibitory potential of bioactive compounds against SARS-CoV-2 by in silico approach.

Researchers investigated the antiviral potential of bioactive compounds from medicinal plants to treat COVID-19. Compounds from Sphaeranthus indicus, Lantana camara, and Nelumbo nucifera showed inhibitory effects against SARS-CoV-2 in molecular docking studies. Consider these natural compounds for potential treatment.

Rani JMS et al (2024).

J Mol Model.

DOI:

10.1007/s00894-024-05858-8

PubMed:

38321299

A randomized, placebo controlled, double blinded, parallel group clinical study to evaluate the efficacy and safety of AEV01 along with standard care for elderly patients with mild COVID-19.

Researchers conducted a study on medicinal plants for COVID-19 treatment and found promising results. Medicinal plants have benefits like better tolerability, compatibility with the human body, and fewer side effects, making them important for healthcare in both developing and developed countries.

Balan AK et al (2024).

J Ayurveda Integr Med.

DOI:

10.1016/j.jaim.2023.100860

PubMed:

38320447

Behavioural activation to mitigate the psychological impacts of COVID-19 restrictions on older people in England and Wales (BASIL+): a pragmatic randomised controlled trial.

Study tested if telephone-based behavioral activation intervention could alleviate depression and loneliness in older adults at risk during COVID-19 pandemic. Results show potential to combat negative mental health impacts in this vulnerable population.

Gilbody S et al (2024).

Lancet Healthy Longev.

DOI:

10.1016/S2666-7568(23)00238-6

PubMed:

38310902

Detection of Schizophyllum commune in SARS-CoV-2 Pneumonia.

Tanabe M et al (2024).

Intern Med.

DOI:

10.2169/internalmedicine.3018-23

PubMed:

38296475

Efficacy and safety of aniseed powder for treating gastrointestinal symptoms of COVID-19: a randomized, placebo-controlled trial.

Aniseed powder may help improve abdominal pain, anorexia, and diarrhea in COVID-19 patients. It has multiple beneficial properties, including inhibiting SARS-CoV-2. Larger trials are needed to confirm these findings.

Mosaffa-Jahromi M et al (2024).

Front Pharmacol.

DOI:

10.3389/fphar.2024.1331177

PubMed:

38292939

Nebulized glycyrrhizin/enoxolone drug modulates IL-17A in COVID-19 patients: a randomized clinical trial.

Glycyrrhizin and its derivative Enoxolone show potential as antiviral treatments. This clinical trial focuses on evaluating the safety and effectiveness of a nebulized GA/18β drug for treating COVID-19 patients.

Zendejas-Hernandez U et al (2024).

Front Immunol.

DOI:

10.3389/fimmu.2023.1282280

PubMed:

38283346